Data from the phase II NP30179 expansion study demonstrated that, after a median follow-up of more than 12 months, fixed-duration glofitamab—an investigational CD20xCD3 T cell-engaging bispecific antibody—induced durable complete responses in patients with relapsed or refractory diffuse large B-cell lymphoma who had received a median of three prior therapies.
The aging process known as senescence is a mechanism involved in the failure of CAR T-cell therapy, according to a study by researchers at the Mayo Clinic.
